Results 121 to 130 of about 30,729 (226)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

Patient Preference and Adherence, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
doaj  

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

The Lancet, 2016
Robert M. Anthenelli, Neal L. Benowitz, R. West, L. S. St. Aubin, T. Mcrae, D. Lawrence, J. Ascher, C. Russ, A. Krishen, A. Evins   +9 more
semanticscholar   +1 more source

The Response of Ventral Tegmental Area Dopaminergic Neurons to Bupropion: Excitation or Inhibition?

Basic and Clinical Neuroscience, 2019
Introduction: Antidepressants can modulate brain monoamines by acting on pre-synaptic and postsynaptic receptors. Autoreceptors can reduce the monoamines effect on the somatodendritic or pre-synaptic regions despite its postsynaptic counter effects.
Shirin Sadighparvar, Fereshteh Tale, Parviz Shahabi, Somayyeh Naderi, Firouz Ghaderi Pakdel   +4 more
doaj  

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

New England Journal of Medicine, 1999
D. Jorenby, S. Leischow, M. Nides, S. Rennard, J. Johnston, Arlene R. Hughes, Stevens S. Smith, M. Muramoto, D. Daughton, Kimberli Doan, Michael C. Fiore, T. Baker   +11 more
semanticscholar   +1 more source

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial

JAMA Internal Medicine, 2018
Neal L. Benowitz, A. Pipe, R. West, J. Hays, S. Tonstad, T. Mcrae, D. Lawrence, L. S. St. Aubin, Robert M. Anthenelli   +8 more
semanticscholar   +1 more source

HKJEM abstracts (Sep & Oct 2026)

Hong Kong Journal of Emergency Medicine, Volume 33, Issue 5, October 2026.
wiley   +1 more source

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2016
S. Nissen, K. Wolski, Lisa Prcela, T. Wadden, J. Buse, G. Bakris, Alfonso T. Perez, Steven R. Smith   +7 more
semanticscholar   +1 more source

Giardiasis and Bupropion-Associated Gastrointestinal Symptoms in a Returning Traveler: A Diagnostic Challenge Case Report. [PDF]

Reports (MDPI)
Liu LT, Zhang X, Hayee S, Fahimuddin M.
europepmc   +1 more source

Single-Agent Bupropion Exposures: Clinical Characteristics and an Atypical Cause of Serotonin Toxicity

Journal of Medical Toxicology, 2019
B. Murray, J. Carpenter, C. Dunkley, T. Moran, E. Kiernan, T. Rianprakaisang, Waleed S. Alsukaiti, D. Calello, Z. Kazzi, On behalf of the Acmt Toxicology Investigators Consortium   +9 more
semanticscholar   +1 more source

Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy. [PDF]

Front Psychiatry
Alanazi AS, Alanazi BA.
europepmc   +1 more source